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Effect of hematocrit on solute removal during high efficiency hemodi-
alysis. The effect of changing hematocrit (Hct) on solute removal during
high efficiency hemodialysis was evaluated in 12 patients. In five
subjects, Hct was raised by recombinant human erythropoietin (r-
HuEPO) treatment, and in the other seven by blood transfusion. Solute
removal was assessed by measuring: (1) whole blood (kb), blood water
(kbw) and dialysate (kd) clearances; (2) the amount of solute in the
spent dialysate; (3) the fractional decrement of serum solute concen-
tration achieved by hemodialysis; and (4) urea kinetics, including kt/V
and protein catabolic rate (PCR). The results showed that increasing the
Hct did result in a slight reduction in some solute clearances. The
decrement, however, was minor (5 to 8%), whereas the rise in Hct was
marked (55 and 65%) in the transfused and EPO-treated groups,
respectively. More importantly, linear regression analysis of kd/kb
ratios versus Hct indicated that a rise of Hct from 20 to 40% would
reduce creatinine and phosphate clearance by 8 and 13%, respectively.
By contrast, assessment of the absolute amount of solute removed in
the spent dialysate failed to detect differences between the two study
periods. Additionally, a rise in Hct also did not affect urea kinetic
parameters including kt/V and PCR. Based on these data, it appears
prudent to increase hemodialysis prescription by 10 to 15% when Hct is
raised to near 40% to avoid excessive retention of molecules with slow
transcellular movement.
As we ushered in recombinant human erythropoietin (r-
HuEPO) to nephrology, one unsettling issue is whether rising
hematocrit might decrease the rate of solute removal during
hemodialysis. This potential problem is especially serious in
patients undergoing rapid high-efficiency hemodialysis. Shinab-
erger and colleagues and Von Albertini and associates have
alerted physicians to the danger of underdialysis following
r-HuEPO administration [1, 2]. The current study represents a
systematic effort attempting to find out whether a higher hem-
atocrit is associated with lower clearance or removal rate of
small molecular weight metabolites.
Methods
Patient selection
Twelve chronic hemodialysis patients participated in this
study. In five of them, the hematocrit was raised by r-HuEPO
administration, and in the other seven by packed cell transfu-
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sion. In the EPO group, there were one woman and four men.
Their ages ranged from 64 to 73 years (mean age was 68.2 3.5
years). In the packed red cell transfusion group, there were four
women and three men. Their age ranged from 23 to 61 years
(mean age was 34.9 13.0 years). Combining the two groups,
the duration of maintenance hemodialysis ranged from eight
months to six years. Diagnoses of their renal diseases included
four with chronic glomerulonephritis, three with rapidly pro-
gressive glomerulonephritis, two with hypertensive nephroscle-
rosis, two with hemolytic uremic syndrome, and one with
diabetic nephropathy. Criteria of selection included anemia
(Hct <25%), absence of intercurrent illness, and willingness to
cooperate in the study.
Study design
Solute removal by high efficiency hemodialysis was measured
twice in each participant: once when the hemotocrit (Hct) was
low and designated as Period A, and again when the Hct was
raised by either packed red cell transfusion or recombinant
human erythropoietin (r-HuEPO) treatment and designated as
Period B. Two consecutive dialyses were studied during each
period. The sequence of the two periods was randomized, and
study dialyses were performed on non-transfusion days.
Each dialysis was monitored and recorded by a research
technician who calibrated dialysate outflow (which included
ultrafiltration rate) and blood inflow rates by timed volumetric
collections during and after dialysis, respectively. Blood and
dialysate samples were obtained at 30 and 90 minutes during
each dialysis. Blood samples were also obtained at the begin-
ning and the end of each study dialysis session as well as the
end of the preceding dialysis. Furthermore, the total spent
dialysate, which included the ultrafiltrate, was collected in a
tared container during each study, and the weight of this
dialysate, corrected for specific gravity (1.003 at 22°C), was
taken as the dialysate volume. Solute concentration in the total
spent dialysate was measured in triplicate. Residual renal
clearance was determined by saving all the urine voided be-
tween two consecutive dialyses. Hct was measured at the
beginning and the end of each dialysis.
In vivo blood and dialysate clearances (kb and kd, respec-
tively) were measured at 30 and 90 minutes for urea nitrogen,
creatinine and phosphate using conventional equations. Be-
cause water content in plasma and erythocytes are different
(93% and 72%, respectively), blood water clearance rates (kbw)
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were also calculated using the equations published by Gotch'
[3]. Additionally, urea nitrogen clearance rate was also calcu-
lated using the direct dialysate quantification method (DDQ)
described by Malchesky and colleagues [41.
Fractional decrement of serum urea nitrogen, creatinine and
phosphate before and after dialysis was determined.
Urea nitrogen, creatinine and phosphate in the spent dialy-
sate were measured. Because the inter-dialytic intervals were
not always 2700 minutes, solute removal rates are presented as
the amount removed per 24 hours.
The adequacy of dialysis, kt/V, as well as the protein cata-
bolic rate (PCR) were assessed independently by the three-
point single-pool variable-volume urea kinetic model (UKM) of
Gotch and Sargent2 [5, 61 and the three-point direct dialysate
quantification (DDQ) proposed by Malchesky and associates
[41. In vivo dialysate clearance (kd) was used to generate the
UKM data. Dialyzer clearance for the DDQ method was
calculated from the urea nitrogen contained in the spent dialy-
sate and the serum urea nitrogen concentration pre- and post-
dialysis.
Dialyses were performed using the Gambro single-pass de-
livery system with an ultrafiltration controller (Gambro, New-
port News, Virginia, USA) and the Duoflux hollow fiber dia-
lyzer (CD Medical, Miami Lakes, Florida, USA). Bicarbonate
was uniformly used as the buffer base. Blood flow rate was set
at 400 mi/mm and dialysate flow rate at 500 mllmin, and the
duration of dialysis was 180 minutes. All study dialyses were
C1[(l — 0.Hct)(0.93 Qa) + 0.Hct(0.72 QB)1
Kbw =
— CB0[(l — 0.Hct)(0.93 QB) — QUF + 0.Hct(0.72 QB)/CE
(CBI CB0){0.93 — 0.21(0.Hct)]Q5 + C80 x Qu/Cai
CBI and CBO solute concentration, respectively, of blood going in and
coming out of the dialyzer, Hct = hematocrit, and Q = ultrafiltration
rate.
2 V = Qur X td — [G — CT2(KT QuF)/G
— C02(KT — QuF)IQ /KT_QUF]_ I —
G = (Kr + B)[C02 — CTI(V + B x tid/V)_Kr+B/BI/
[1 — (V ÷ B >< tidV)'J
V = urea volume, G = urea generation rate, KT sum of dialyzer and
renal clearances, Kr = residual renal clearance, td and tid = time on
dialysis and time in between dialyses, respectively, C02 and CT2 =
BUN at the beginning and the end of the study dialysis, CT1 = BUN at
the end of preceding dialysis, and B interdialytic weight gain/tid, and
QUF dialytic weight loss/td.
VdXCd+VuXCu=V(C02—CT2)+GXtd
V = [Vd x Cd + Kr(C02 ÷ CT2/2)td — G X tdj/(C02 — CT2)
G = [V(C02 — CT ,)/tidj + [Kr(C02+ CT 1/2)1
KT = (— V/td )ln(CT2/C02)
Vd = volume of the total spent dialysate, Cd = urea nitrogen concen-
tration in the spent dialysate. Vu and Cu = volume of urine and urea
nitrogen concentration in the urine. Kr = residual renal clearance and
KT = sum of dialyzer and renal urea clearance (Since Kr is very small,
KT is taken to be Kd, the dialyzer clearance). Ln = natural log.
performed on the same week days during the two periods with
two-day interdialytic intervals. In other words, the studies were
always done on either Wednesdays and Fridays for some or
Thursdays and Saturdays for other patients. For each partici-
pant, the equipment, dialyzer, tubings, needle, and dialysate
were identical during both periods. Protein intake varied be-
tween individuals from 0.8 to 1.2 glkg/day, but was similar
during both periods. Medication, including phosphate binder,
was also unchanged.
The experimental protocol was approved by the Committee
on Human Research at the University of Iowa College of
Medicine.
Laboratory procedures
Urea nitrogen, creatinine and phosphate in serum and dialy-
sate were measured by the Technicon Auto Analyzer (Techni-
con Instruments Corp., Tarrytown, New York, USA), Serum
samples were determined in duplicate, and dialysate samples in
triplicate; the mean value of each sample was used in the
calculation. Urea nitrogen determination is based on the reac-
tion between urea and diacetyl monoxine under acidic condi-
tions. Thiosemicarbizide buffer was used to intensify the color
of the reaction product which was read at 520 mu. Creatinine
assay was determined by a modified Jaffe reaction with the use
of picric acid in the presence of alkali. The reaction was carried
out at room temperature and read at a wavelength of 505 mu.
Determination of inorganic phosphate was based on the forma-
tion of phosphomolybdic acid which was then reduced by the
addition of stannous chioride-hydrazine. Beckman Decision
Control Sera were used as internal standards to check the
accuracy of the measurement.
The methods described above were sufficiently sensitive to,
at least, accurately measure a urea nitrogen concentration of 5.0
mg/dl, a creatinine concentration of 0.2 mgldl, and a phospho-
rus concentration of 0.5 mg/dl. The coefficients of variation of
the methods of measurement were 4.2%, 5.3%, and 3.9%,
respectively, for urea nitrogen, creatinine and phosphate.
Data analysis
All data were entered into the Clinfo Data Management
System of the Clinical Research Center at the University of
Iowa. Statistical analysis, including Student's and paired t-tests
and linear regression analysis were performed as needed.
Results
Changes in hematocrit
In the seven patients who received packed red cells, mean
pre-dialysis Hct before transfusion was 17.9 1.7%. After
transfusion, mean hematocrit increased to 27.6 2.5% pre-
dialysis and 31.4 3.6% post-dialysis. In the five subjects who
received r-HuEPO, mean baseline pre-dialysis hematocrit was
21.7 1.7%. After treatment, pre-dialysis hematocrit rose to
36.2 4.3% and post-dialysis hematocrit to 39.5 4.2%. The
amount of packed cells transfused ranged from 3 to 4 units, and
the dose of r-HuEPO ranged from 119 to 174 units/kg/week. The
Hct values listed in the Table 1 are derived from means of pre-
and post-hemodialysis values of individual participants. As
noted in the Table footnote, hematocrits were markedly dif-
ferent between periods A and B in both groups of patients.
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Table 1. The effect of hematocrit on dialyzer clearance and solute removal during high efficiency hemodialysis
Group!
period Hct % Solute
Kb Kbw Kd KDDQ Pre/post
reduction
%
Removal
g/24 hrmi/mm
EPO-A 22.9 1.4k urea 238 8 209 8 198 14 159 14 64.2 3.6 6.51 1.93
EPO-B 37.8 4.2a 226 14 193 12 188 16b 146 13b 61.6 4.9 6.80 2.31
P 0.0001 0.023 0.003 NS NS NS NS
T-A 19.1 2.0 240 12 214 11 204 13 163 22 66.4 9.8 7.28 2.20
T-B 29.5 3.0 230 15 201 13 208 10 161 9 62.7 6.0 8.24 2.81
P 0.0001 0.011 0.001 NS NS 0.015 NS
EPO-A cr 182 13 162 11 160 12 55.8 3.1 0.88 0.32
EPO-B 179 8" 153 7" 147 9" 54.3 3.7 0.84 0.43
P NS NS 0.012 NS NS
T-A 185 9 165 7 164 9 60.3 8.3 1.17 0.46
T-B 190 8 166 8 156 8 57.5 6.9 1.17 0.46
P NS NS 0.03 0.03 NS
EPO-A
EPO-B
P04 171 12
185 24
152 11
159 22
126 19
116 9'
41.0 10.1
41.9 10.5
0.36 0.07
0,33 0.15
P NS NS NS NS NS
T-A 176 12 160 12 132 14 46.2 12.7 0.40 0.16
T-B 180 11 162 8 134 9 52.6 8.9 0.42 0.15
P NS NS NS NS NS
EPO-A and -B represent groups of patients before and after r-HuEPO treatment. T-A and -B represent groups of patients before and after packed
cell transfusion, Kb, Kbw, and Kd represent, respectively, whole blood, blood water and dialysate clearance, and KDDQ is clearance calculated
from the direct dialysate quantification method. Fractional reduction (%) is derived from serum concentrations (Pre — Post/Pre) x 100%. Removal
is the absolute amount of the solute in the spent dialysate expressed as g/24 hr. All values are presented as means SD.
Differences between the two periods were assessed by paired (-test and the P values are listed under each group. Differences between the two
groups during each period were evaluated by Student's (-test, and significant values are indicated by a P < 0.0001 and b P < 0.01.
Furthermore, hematocrits of the EPO group were significantly
higher than those of the transfused patients.
Effect of hematocrit on blood clearances and mass
solute removal
As summarized in Table 1, no difference was noted in any of
the clearances between the EPO and the transfusion groups in
the basal state or Period A. By contrast, during Period B, all
clearances, including those of urea, creatinine and phosphate,
were significantly lower in the EPO treated patients. Within the
same groups, the clearances decreased as the hematocrit was
increased. It should, however, be emphasized that the reduc-
tion in the clearances were rather minor, in the order of 5 to 8%
as compared to 55% and 65% increments in hematocrits in the
transfusion and EPO groups, respectively.
As expected, clearances obtained from the blood water
compartment (kbw) were universally lower than whole blood
clearances (kb). For urea and creatinine, clearances obtained
from the blood water compartment (kbw) were in close approx-
imation to the clearances obtained from the dialysate (kd). In
the case of phosphate, kd was persistently lower than simulta-
neously measured kbw.
Another way to assess the effect of hemodialysis is to
examine the fractional reduction of pre- and post-dialysis serum
solute concentrations, assuming that there is no significant
re-equilibration. Using this criteria, no significant changes were
observed between the two study groups or the two periods.
Table 1 also reports the absolute amount of urea nitrogen,
creatinine and phosphate removed in the spent dialysate, and
changing hematocrits did not alter the mass removal measured
by this method.
In Table 2, we summarize the relationship between mass
removal, represented by kd, and hematocrit. Linear regression
analysis of the ratio of dialysate clearance and whole blood
clearance (kdlkb) to hematocrit disclosed a significant negative
correlation between these two parameters for creatinine and
phosphate (P = 0.001 and 0.008, respectively, Fig. lB and 1C),
but not for urea nitrogen (P = 0.66, Fig. lA). While the kd/kb
ratios were unchanged for urea nitrogen during this study, such
ratios for creatinine and phosphate fell significantly when
hematocrits increased from 16 to 44%. Based on these regres-
sion lines, an increase of Hct from 20% to 40% would reduce
creatinine removal by 8% and phosphate removal by 13%.
Effect of hematocrit on urea kinetics
The urea kinetic data in Table 3 showed that all subjects were
adequately dialyzed with the current regimen in accordance
with the criteria published by the National Cooperative Dialysis
Study recommending a kt/V of at least 0.8 and a minimum
protein intake of 0.8 g/kg/day [7]. Increasing the hematocrit did
not adversely reduce the adequacy of hemodialysis as measured
by kt/V. Both the UKM and the DDQ methods found the kt/V
and the protein catabolic rate to be stable and unaffected by
r-HuEPO treatment or blood transfusion.
Table 3 also shows that the two study groups were different.
The EPO subjects, compared to the transfusion patients, were
older, more obese and had a smaller urea volume. This group of
participants also had lower dietary protein intake. These differ-
ence in the study patients, however, should not affect clearance
parameters and should also not invalidate the comparison of
each group within itself during periods when hematocrits were
changed.
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Table 2. Effect of hematocrit on mass removal to whole blood clearance ratio
Solute K a
Kd/Kb P
paired t
test DF
F
value Slope r
P
regression
analysis(low Hct) (high Hct)
Urea
Creatinine
P04
0.859
0.731
0.500
instantly
4.4%/mm
very slow
0.84 0.01
0.89 0.06
0.75 0.09
0.87 0.09
0.82 0.06
0.68 0.09
0.28
0.004
0.05
51
50
50
0.199
12.190
7.640
0.0008
—0.004
—0.005
0.06
—0.44
—0.36
0.658
0.001
0.008
Data from all subjects and both periods were combined for the linear regression analysis correlating the ratios of kd/kb to hematocrits. K is the
ratio of RBC/plasma concentration or the fraction of effective solute volume in RBC as compared to the total RBC volume, a is the rate of solute
diffusion from RBC to the plasma. The mean low Hct in period A was 20.7 2.6, and the mean high Hct in period B was 32.2 5.4; individual
Hct ranged from 19.6 to 42.0%.
While there was no correlation between kd/kb of urea and hematocrits, negative correlation between kd/kb of creatinine and phosphate to
hematocrits was noted.
The N (number of dialysis) used in this linear regression study is 54, 6 dialyses more than the 48 paired dialyses. We had planned to use these
6 dialysis for paired studies, but due to some uncontrolled circumstances, the intended repeat studies were not completed. Because of their variable
hematocrits, we have decided to include them in this analysis.
•.
.
Fig. 1. Effect of hematocrits on solute removal. (A) Urea nitrogen removal [kd/kbure = 0.845 + 8.1 1e4 X Hct, r = 0.06, P = 0.66] was not altered
by Hct. By contrast, (B) creatinine removal [kd/kbcr = 0.966 + (—0.004 x Hct), r = —0.44, P = 0.001] and (C) phosphate removal [kd/kb4 =
0.854 + (—0.005 X Hct), r = —0.36,P = 0.008] were inversely related to hematocrits. An increase of hematocrit from 20% to 40% would reduce
creatinine clearance by 8% and phosphate removal by 13%.
Effect of hematocrit on midweek pre-dialysis blood
chemistries
For the five r-HuEPO treated patients, the interval between
the two studies ranged from 35 to 84 days; the mean interval (±
sD) was 61.6 20.0 days. Mean midweek pre-dialysis serum
concentration of urea nitrogen, creatinine, potassium and phos-
phate in the period before r-HuEPO were, respectively, 69.1
8.1 mg/dl, 9.7 2.0 mg/dl, 4.99 0.47 mEq/liter and 4.13
0.72 mg/dl. During r-HuEPO treatment, the respective mean
pre-dialysis serum concentration of urea nitrogen, creatinine,
potassium and phosphorus were 63.7 7.6 mg/dl, 10.10 2.2
mgldl, 5.10 0.45 mEq/liter and 5.06 0.92 mg/dl. The values
before and after r-HuEPO were not different for urea nitrogen,
creatinine and potassium, but were higher for serum phosphate,
P = 0.037 by paired 1-test. For every subject, at least two sets
of monthly tests were used to generate the mean values.
In the seven transfused patients, mean mid-week pre-dialysis
serum urea nitrogen, creatinine, potassium, and phosphate
were not different before and after transfusion.
Discussion
The addition of recombinant human erythropoietin (r-
HuEPO) to the nephrology armamentarium is touted as one of
the most important therapeutic advancements in the last decade
[8, 9]. While the effectiveness of r-HuEPO in raising Hct has
been proven beyond doubt [8—i 1], the potential side effects
have not been addressed in depth. One such unwanted effect is
reduced solute removal during hemodialysis.
Eschbach and colleagues and Casati and associates reported
that hyperkalemia is seen more frequently in patients receiving
r-HuEPO [8, 121. It is not clear whether the observed hyper-
kalemia was attributable to increased dietary intake or de-
creased dialytic removal as a consequence of a higher hemato-
crit. Since removal of solutes by the process of hemodialysis is
dependent on the flow of the solute from the blood water
compartment to the dialysate, it is comprehensible that as the
fraction of water in the blood is reduced by raising the Hct,
removal of such solute may be reduced. If, however, a mole-
cule's concentration within the red cells is comparable to that of
the serum, and if the rate of diffusion of that solute from the red
cells to the serum is rapid, then changing the hematocrit may
not affect its removal. Urea has a red cell/plasma concentration
ratio close to unity and a red cell to plasma transfer rate that is
higher than most dialyzer clearance rate [1, 13, 14]. Thus, one
would expect only minor changes of urea clearances as the Hct
is raised, a contention supported by our data. Furthermore, the
A BUN
1.2
1.0
B CR C P04
0.8
.0.6
0.4 I I I I I I
20 30 40
Hct
I I I I I I
20 30 40 20
Hct Hct
30 40
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Table 3. Effect of hema tocrit on urea kinetics and protein metabolism in hemodialysis patients
Group!
period Method Age Body wt kg
Urea volume
Kt/V
NPCR
g/kg/24 hr(L) %BW
EPO-A UKM 68.2 35 73.5 6.8" 34.8 5.7 7• 1.21 0.13 0.98 0.20C
EPO-B 72.9 7.3" 33.0 4.8 45,2 45 1.17 0.15 1.08 0.25
P NS NS NS NS NS
T-A 34.9 13.0 60.9 15.6 32.8 7.1 54.7 5.9 1.32 0.36 1.28 0.40
T-B 61.4 15.6 34.7 6.4 58.0 7.7 1.19 0.19 1.31 0.31
P NS NS NS 0.036 NS
EPO-A DDQ 32.0 7.2 43.4 7.3 1.04 0.10 0.94 0.19C
EPO-A 30.2 5.4 41.3 4.8 0.97 0.13 1.02 0.24Cp NS NS NS
T-A 31.8 8.1 52.5 5.5 1.13 0.30 1.14 0.28
T-B 30.9 6.2 51.4 6.5 1.00 0.16 1.24 0.25
P NS 0.01 0.035
Group and period designation is identical to that of Table 1. All values are presented as means su. UKM and DDQ indicate the method of
derivation by urea kinetic model and direct dialysate quantification, respectively. NPCR denotes normalized protein catabolic rate = PCRI(V/0.58)
in which V is the calculated urea volume and PCR = (G x 1.44) + 1.7/0.154 (G is urea generation rate derived from urea kinetics).
Differences between the two periods were evaluated by paired t-test and the P values are listed under each group. Differences between the two
groups during each period were assessed by Student's t-test and significant values are indicated by a P < b P < 0.01 and C P < 0.05.
index of dialysis adequacy, kt/V, was also unchanged as the Hct
rose. More importantly, regression analysis of the ratio of mass
removal/whole blood clearance (kd/kb) versus hematocrit
showed that changing hematocrits from 16 to 44% did not affect
urea clearance (Fig. 1A).
On the other hand, clearance of molecules with slower red
cell to plasma transfer rates appeared to be more susceptible to
the effect of changing hematocrit levels. Creatinine has an
erythrocyte/plasma ratio of 0.731 and a red cell to plasma
transfer rate of 4.4%/mm. Regression analysis of its kd/kb
versus Hct showed a significant negative correlation between
these two parameters; r = —0.44 and P was 0.001 (Fig. IB).
Phosphate has an erythrocyte/plasma ratio of 0.500 and a red
cell to plasma transfer rate that is very slow. Thus, the kd/kb
ratio of phosphate was also noted to be inversely correlated
with Hct; r = —0.36 and P = 0.008 (Fig. lC). Based on these
regression analysis, one may expect a reduction of creatinine
and phosphate removal by 8% and 13%, respectively, when
hematocrit is increased from 20 to 40%.
Data derived from direct dialysate quantification, however,
were unimpressive; the absolute amounts of urea, creatinine
and phosphate in the spent dialysate were not different during
periods of low and high hematocrits. We believe that this
discrepancy is methodological and that data derived from kd
and kb measurements are more accurate than that derived from
spent dialysate quantification. The rationale for this statement
is based on the fact that errors encountered in the chemical
determination are multiplied a thousand-fold because of the
large volume of the dialysate, usually approximately 100 liters.
For example, if a small error of 0.1 mg/dl is noted in dialysate
phosphate concentration, the magnified error for the total spent
dialysate would be 100 mg. Please note that the removal rate of
phosphate was about 400 mg124 hours, direct dialysate quanti-
fication, therefore, cannot detect a 12.5% change in mass
balance.
The lower dialyzer clearance obtained with the direct quan-
tification method is well known (Table 1), and is due mainly to
the fact this clearance is not directly measured (as in the UKM
method), but is calculated from serum urea nitrogen concentra-
tion before and after dialysis. Such estimation is greatly influ-
enced by urea dysequilibrium.
Shinaberger, Miller and Gardner have alerted nephrologists
that r-HuEPO treatment may lead to increased blood viscosity
and increased filtration pressure on the blood compartment
resulting in excessive obligatory fluid loss and, perhaps, back
filtration of dialysate [1]. Using a volumetric fluid controller, we
have not encountered any problem with ultrafiltration, in fact,
net ultrafiltration was comparable during periods of low and
high hematocrits. We also have not encountered any pyrogen
reaction to suggest dialysate back filtration. It should be noted
that the dialyzer used in the current study, Duoflux, has an
ultrafiltration coefficient of 15 mI/hr/mm Hg. It is possible that
one may encounter problems with the use of higher flux
membrane.
In summary, the current study showed that varying hemato-
crits from 16 to 44% did not adversely affect urea nitrogen
clearance, but did significantly reduce creatinine and phosphate
clearances. Any substance that has a slow coefficient of transfer
from the red cells to the serum, and is dependent on serum
water clearance, notably phosphate and creatinine, will be
significantly and proportionately reduced by increased hemato-
crit levels. We have also shown that the conventionally-used
whole blood clearance is a poor estimate of actual solute
removal. If blood clearance is to be used, correction should be
made to calculate blood water clearances. Furthermore, it
appeared that the best estimate of solute removal is accom-
plished by measurement of dialysate clearance.
If adequacy of dialysis is measured only by urea nitrogen
clearance, then an increased hematocrit does not necessitate a
change. If removal of other substances such as phosphate and
potassium are important, then the prescription of hemodialysis
should be increased by 10 to 15% when the hematocrit raises to
near 40%. It must be emphasized that these conclusions are
applicable only to high efficiency hemodialysis since the effect
of changing hematocrits on high flux dialysis and hemodiafiltra-
tion have not yet been assessed.
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